Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

Bausch + Lomb Launches Blink(TM) Triple Care Preservative Free Lubricant Eye Drops in the United States

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

By The Northwire Desk — AI Analysis Jun 01, 2026 · 06:59 BLCO · 21.62 BAUSCH + LOMB CORPORATION
Executive Summary
  • Bausch + Lomb announced the U.S. launch of Blink Triple Care Preservative Free eye drops, expanding its dry eye relief portfolio with a lipid-based, preservative-free formulation.
  • The product delivers clinically proven 3-in-1 extended relief, locking in moisture for up to 10 hours, and will be available nationwide at major retailers and online by the end of June 2026.
  • This launch follows a clear progression of product rollouts: the November 2025 Investor Day outlined a $7 billion peak-sales pipeline, followed by the April 2026 FDA clearance for the Bi-Blade+ cutter, the European launch of the enVista Envy IOL, and the May 2026 launch of PreserVision AREDS3 vitamins.
  • The June 1 announcement aligns with the company's previously disclosed roadmap and complements the Q1 2026 earnings release, which raised full-year guidance based on strong dry eye and pharmaceutical growth.
  • Management emphasizes growing consumer demand for preservative-free options driven by prolonged screen time and environmental factors, positioning the product to capture patients with sensitivities or evaporative dry eye.
Material Impact
  • The launch is a routine, incremental product expansion that was already priced into the company's 2026 guidance. It does not represent a fundamental shift in the business model or a surprise catalyst.
  • Historical progression shows management consistently executing on the Investor Day pipeline, but each product launch has delivered marginal financial upside rather than step-change revenue jumps.
  • The dry eye category remains a core growth driver, yet the preservative-free variant targets a niche within an already saturated OTC market. Gross-to-net pressures and competitive pricing could limit near-term margin contribution.
  • Financial impact is expected to be modest, contributing to the already raised full-year revenue ($5.42B–$5.52B) and EBITDA ($1.01B–$1.06B) guidance. The news reinforces execution but lacks the magnitude to alter the stock's valuation multiple.
  • The transcript confirms that dry eye portfolio growth (MIEBO +33%, XIIDRA +30%) is the primary earnings driver, while surgical segment recovery remains a work in progress due to field force rebuilding and weather disruptions.
BLCO · Price
Company Overview
  • Bausch + Lomb is a leading global eye health company operating across Vision Care, Surgical, and Pharmaceuticals segments.
  • Flagship products include the dry eye portfolio (MIEBO, XIIDRA, Blink), LUMIFY redness reliever, and premium intraocular lenses (enVista).
  • The company is undergoing a transformation focused on margin expansion, debt reduction, and pipeline commercialization, targeting ~23% adjusted EBITDA margin by 2028.
  • The $7 billion peak-sales pipeline spans consumer, pharmaceutical, surgical, and contact lens innovations through 2031.
  • Recent milestones include FDA clearance for the Bi-Blade+ vitrectomy cutter, the European launch of the enVista Envy IOL, and positive Phase 2 data for the Elios glaucoma laser.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other Apr 29, 2026 · 06:58

Bausch + Lomb Beats Q1 Estimates but Debt Overhang Persists Amid Turnaround Execution

Earnings